News
order by visits date title

Meet us at DCAT in New York!

We invite you to join us in our meeting room at the Intercontinental Suite #510/511 and learn more about our capabilities: Solid Form Development Crystallization Optimization Analytical Services In order to schedule a meeting please contact luca.covello@polycrystalline.it.

Read all

Meet us at DCAT in New York!

We invite you to join us in our meeting room at the Intercontinental Suite #510/511 and learn more about our capabilities: Solid Form Development Crystallization Optimization Analytical Services In order to schedule a meeting please contact luca.covello@polycrystalline.it.

Read all

MyCrystalPro: Our Online Portal

From our experience a shared over-view is what enables effective communication within a group. In order to offer an added value to our clients at Polycrystalline we developed our own web portal for project communication named MyCrystalPro. MyCrystalPro stands for “My Crystalline Project”, because at Polycrystalline we offer a transparent and streamlined partnership, with joint responsibilities and interactions. In our unique interface there are four major features that summarize our governance: E

Read all

MyCrystalPro: Our Online Portal

From our experience a shared over-view is what enables effective communication within a group. In order to offer an added value to our clients at Polycrystalline we developed our own web portal for project communication named MyCrystalPro. MyCrystalPro stands for “My Crystalline Project”, because at Polycrystalline we offer a transparent and streamlined partnership, with joint responsibilities and interactions. In our unique interface there are four major features that summarize our governance: E

Read all

Polymorphs of Dex-Lansoprazole

  New Crystalline Forms of Dex-Lansoprazole Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Kapidex (dexlansoprazole). This DEP002 product contains a new and stable crystal of dexlansoprazole which circumvents Takeda’s intellectual property. Kapidex is a proton pump inhibitor that obtained FDA approval in 2009 by Takeda Pharmaceuticals for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GE

Read all

Pagina 2 di 3
© Copyright Polycrystalline SpA - All rights reserved - VAT IT02600021204 / powered by DibiWeb